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Abstract 
 
Objective: Extant epidemiologic data of primary Sjögren’s Syndrome (pSS) remains 
limited, particularly for racial/ethnic populations in the United States (US). The 
Manhattan Lupus Surveillance Program (MLSP), a population-based retrospective 
registry of cases with Systemic Lupus Erythematosus and related diseases including 
pSS in Manhattan, was used to provide estimates of the incidence and prevalence of 
pSS across major racial/ethnic populations. 
Methods: MLSP cases were identified from hospitals, rheumatologists, and population 
databases. Three case definitions were used for pSS: physician diagnosis, 
rheumatologist diagnosis, and modified pSS criteria. Rates among Manhattan residents 
were age-adjusted, and capture-recapture analyses were conducted to assess case 
under-ascertainment.  
Results: By physician diagnosis, age-adjusted overall incidence and prevalence rates 
of pSS among adult Manhattan residents were 3.5 and 13.1 per 100,000 person-years. 
Capture-recapture adjustment increased incidence and prevalence rates (4.1 and 14.2). 
Based on physician diagnosis, incidence and prevalence rates were approximately 6 
times higher among women than men (p<0.01). Incidence of pSS was statistically 
higher among non-Latina Asian (10.5) and non-Latina White women (6.2) compared 
with Latina women (3.2). Incidence was also higher among non-Latina Asian women 
compared with non-Latina Black women (3.3). Prevalence of pSS did not differ by 
race/ethnicity. Similar trends were observed when more restrictive case definitions were 
applied.   
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Conclusion: Data from the MLSP revealed disparities in pSS incidence and prevalence 
by sex among Manhattan residents and differences in pSS incidence by race/ethnicity 
among women. These data also provided epidemiologic estimates for the major 
racial/ethnic populations in the US.  
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Significance and Innovations 
• This is the first population-based multi-racial/ethnic study in the United States to 
report on the epidemiology of Sjögren’s Syndrome where existing data are sparse in 
the literature.  
• Our study revealed disparities in Sjögren’s Syndrome incidence and prevalence by 
sex among Manhattan residents and differences in incidence by race/ethnicity among 
women.  
• These data also provided epidemiologic estimates for the major racial/ethnic 
populations in the US. 
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Sjögren’s Syndrome (SS) is a chronic systemic autoimmune disease that manifests as 
oral and ocular dryness and parotid gland enlargement due to lymphocytic infiltration of 
exocrine glands, in addition to multi-organ-system extraglandular involvement (1). This 
syndrome can occur in the absence or presence of other systemic rheumatologic or 
autoimmune diseases such as Systemic Lupus Erythematosus (SLE), referred to as 
primary or secondary, respectively. The epidemiology of SS remains limited with few 
published estimates for the general population and minimal data on multi-racial/ethnic 
populations in the United States (US) (2, 3). 
The Manhattan Lupus Surveillance Program (MLSP) was initiated in 2010 as a 
collaboration between the New York City Department of Health and Mental Hygiene 
(DOHMH) and NYU School of Medicine (NYUSoM) (4). The primary goal of the MLSP 
was to determine incidence and prevalence of SLE among Manhattan residents. To 
accomplish this, a retrospective population-based registry was established with 
extensive information obtained on SLE as well as other autoimmune rheumatic 
diseases including SS. Leveraging this rich data source, we provide incidence and 
prevalence estimates of primary SS (pSS) during 2007 and 2007-09, respectively, 
among Manhattan residents across the major racial/ethnic populations (Black, Latino, 
Asian, White).  
Methods 
The Manhattan Lupus Surveillance Program 
The MLSP is one of five registries funded by the Centers for Disease Control and 
Prevention (CDC) to provide credible estimates for the incidence and prevalence of SLE 
(4-8). Details on the MLSP have been previously reported (4). In brief, medical records 
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were reviewed under the health surveillance exemption to HIPAA privacy rules [45 CFR 
§ 164.512(b)] and as authorized by New York City Charter Sections 556(c)(2) and 
(d)(2). No cases were contacted for this project. The CDC deemed the various SLE 
surveillance programs public health practice, which did not require institutional review 
board (IRB) review, and IRBs at both DOHMH and NYUSoM deemed the MLSP a 
surveillance activity. When requested, additional IRB applications were completed and 
submitted to independent case-finding sources. The DOHMH IRB reviewed and 
approved secondary analyses on a de-identified dataset.  
The MLSP surveillance period was January 1, 2007, through December 31, 2009. 
Manhattan was selected for reasons previously described (4). In 2010, based on US 
Census data, there were 1,585,873 persons residing in Manhattan (48% non-Latino 
White, 13% non-Latino Black, 25% Latino, 11% non-Latino Asian) (9). 
Case Ascertainment, Data Collection, and Quality Control of Data Entry 
The MLSP used the following sources to identify cases: rheumatologists’ practices 
(including pediatric rheumatologists), hospitals, and administrative hospitalization 
discharge and death registry databases (4). Case finding sources were queried 
retrospectively, as far back as 2004 when available, for evidence of residence in 
Manhattan and International Classification of Disease Ninth Revision Clinical 
Modification (ICD-9CM) billing codes specific for SLE, discoid lupus, and related 
conditions that may evolve into SLE or have related symptoms including SS. The ICD-
9CM codes used to identify cases included 710.0 (SLE), 695.4 (discoid lupus), 710.8 
(other specified connective tissue disease), 710.9 (unspecified connective tissue 
disease), and 710.2 (Sicca syndrome which is used for SS). Charts for every patient 
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who lived in Manhattan and had one of the respective ICD-9CM codes were fully 
abstracted and final diagnosis was coded. Abstraction was completed in 90.5% of 
hospitals and 75.8% of rheumatologists’ practices by trained abstractors, all of whom 
had medical degrees and underwent extensive training and routine quality assurance as 
previously described (4).  
Case Definitions 
The MLSP was constructed for surveillance of SLE, and data elements collected 
focused on two widely used classification schemes for SLE: the American College of 
Rheumatology (ACR) Criteria (10, 11) and the Systemic Lupus International 
Collaborating Clinics (SLICC) (12). Additional manifestations commonly associated with 
SLE – even if not specifically included as a criterion for classification – were also 
captured, allowing for the potential to identify evidence of SS. Given the overlapping 
nature of the clinical manifestations of these autoimmune diseases, several but not all of 
the American-European Consensus Group (AECG) (13) criteria for SS (most recent 
available at time of data dictionary development) were captured. For criteria regarding 
the diagnosis of SS not systematically captured, abstractors were trained to take 
detailed text notes including results of minor salivary gland biopsies and objective 
results of ocular and oral tests.  
Because this analysis focused on pSS, we excluded cases diagnosed with other 
rheumatologic diseases such as SLE, despite having an additional diagnosis of SS. 
Also, given the rarity of childhood pSS, we only included cases aged ≥18 years in our 
analyses (14).  
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The diagnosis of SS is usually made by a physician familiar with the disease, often but 
not exclusively by a rheumatologist.  Thus, our primary case definition for pSS required 
documentation of a pSS diagnosis by any physician, and our more conservative 
secondary case definition required documentation of a pSS diagnosis by a 
rheumatologist. In the MLSP, few cases met the AECG (13), ACR (15), and the more 
recent ACR/European League Against Rheumatism (EULAR) criteria for pSS (16). 
Thus, we developed a third, more restrictive, case definition, slightly modified from the 
recent ACR/EULAR criteria (16), requiring documentation of all of the following criteria: 
a) pSS diagnosis by any physician, b) documentation of dry eyes and/or dry mouth, and 
c) a positive test for anti-SSA antibody.  
Statistical Analysis 
Incident cases were those aged ≥18 years meeting a pSS case definition, residing in 
Manhattan, and first diagnosed with pSS from January 1, 2007, through December 31, 
2009.  Prevalent cases were new or existing cases among those aged ≥18 years 
meeting a pSS case definition residing in Manhattan from January 1 - December 31, 
2007.  DOHMH intercensal population estimates for Manhattan were used to calculate 
denominators (9).  
Rates were calculated overall, by sex, and by race/ethnicity per 100,000 person-years 
and age-adjusted to the US 2000 standard population using 10 year age groups within 
each racial/ethnic group (17). Although data on race and Latino ethnicity were collected 
separately during abstraction, cases were assigned to one of five mutually exclusive 
race/ethnicity categories: non-Latino White, non-Latino Black, non-Latino Asian, Latino, 
and non-Latino other. Non-Latino cases identified with more than one race were 
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categorized as other. Chi-square tests or Fisher’s exact tests were used to determine if 
age-adjusted pSS proportions differed by sex and race/ethnicity. When significant 
differences were found by race/ethnicity, pairwise differences were evaluated using z-
tests assuming the Poisson distribution and statistical significance at 0.05, with 
Bonferroni correction to 0.008. 
Capture-recapture analyses were performed (18, 19) to estimate case under-
ascertainment; specific methods have been described elsewhere (4). Log-linear models 
were fit separately for incident and prevalent cases by sex and race/ethnicity for 
physician-diagnosed cases and by race/ethnicity alone for cases diagnosed by a 
rheumatologist or meeting the modified case definition due to small numbers.  
All analyses were completed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA) 
and R version 3.3.0 (R Foundation for Statistical Computing, Vienna, Austria). 
Results 
Incidence Rates 
From 2007-2009, 138 incident cases had a physician diagnosis of pSS and 84 had a 
rheumatologist diagnosis of pSS. The overall crude and age-adjusted incidence rates 
for physician-diagnosed cases of pSS were 3.4 (95% confidence interval [CI] 2.9-4.0) 
and 3.5 (95% CI 2.9-4.1) per 100,000 person-years, respectively (Table 1). The overall 
crude and age-adjusted incidence rates for rheumatologist-diagnosed cases of pSS 
were 2.1 (95% CI 1.7-2.6) and 2.1 (95% CI 1.7-2.6) per 100,000 person-years. Age-
adjusted rates differed by sex, and were approximately six to seven times higher for 
women compared with men for both physician- (p<0.001) and rheumatologist-diagnosed 
pSS (p<0.001). The incidence of physician-diagnosed pSS differed by race/ethnicity 
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(p<0.001), with higher rates among Asians (6.2, p=0.002) and Whites (3.8, p=0.006) 
compared with Latinos (2.0). Incidence of physician-diagnosed pSS was also higher 
among Asians compared with Blacks (2.2, p=0.005). Similarly, incidence rates also 
differed by race/ethnicity among women (p<0.01) and were higher among Asian (10.5, 
p=0.002) and White women (6.2, p=0.007) compared with Latina women (3.2), and 
among Asian women compared with Black women (3.3, p=0.003). There was no 
significant difference in age-adjusted incidence of physician-diagnosed pSS by 
race/ethnicity among men (p=0.859). Incidence of rheumatologist-diagnosed pSS also 
differed by race/ethnicity overall (p=0.001) and among women (p=0.001), with higher 
rates among Asian women compared with Latina (p=0.007) and Black women 
(p=0.006). Capture-recapture adjustment estimated 166.7 incident cases of physician-
diagnosed pSS, indicating that 17.2% of cases were missed. Among those missed, 
58.9% were White women. The resulting capture-recapture adjusted incidence rate 
increased to 4.1 per 100,000 person-years (95% CI 2.5-5.8).  
The average age (± standard deviation [SD]) at physician diagnosis of pSS was 52.7 (± 
18.1) years among women and 58.1 (± 17.3) years among men. The average age (± 
SD) at diagnosis among incident cases was 56.0 (±19.1) years among Latinos, 54.7 
(±18.5) years among Whites, 48.6 (±12.0) years among Blacks, and 47.4 (±18.1) years 
among Asians.  
Among Latino pSS cases, 77.8% of those diagnosed by a physician and 77.8% of those 
diagnosed by a rheumatologist were also identified as White. Ethnicity information 
among Latinos was often absent, with two-thirds having no further information available. 
For those with more detail, ethnicities included Central or South American, Dominican, 
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Puerto Rican, and Spanish. Among the physician- and rheumatologist-diagnosed 
incident Asian cases, over one-third had no further data available. Among Asian pSS 
cases diagnosed by a physician or rheumatologist, >25% had no further classification 
for Asian ethnicity. Ethnicities among cases with information available included Chinese, 
Indian or Pakistani, Japanese, and Thai. 
Table 2 shows the serologic and clinical manifestations of pSS captured in the MLSP for 
incident cases of physician- and rheumatologist-diagnosed pSS. Data ascertainment 
was more complete for cases with a rheumatologist diagnosis.  Anti-nuclear antibodies 
(ANA) and anti-SSA/Ro were the most commonly found serologic manifestations among 
both physician- and rheumatologist-diagnosed cases. Extraglandular manifestations 
were present in 62.6% and 65.4% of physician- and rheumatologist-diagnosed cases, 
with lymphopenia and arthritis being the most common. 
Prevalence Rates for pSS  
In 2007, a total of 166 cases had a physician diagnosis of pSS and 94 had a 
rheumatologist diagnosis of pSS. The crude and age-adjusted prevalence of physician-
diagnosed pSS overall was 12.4 (95% CI 10.5-14.3) and 13.1 (95% CI 11.1-15.1) per 
100,000 person-years (Table 3). The overall crude and age-adjusted prevalence of 
rheumatologist-diagnosed pSS were lower, at 7.0 (95% CI 5.7-8.6) and 7.3 (95% CI 5.9-
8.9) per 100,000 person-years. Age-adjusted rates were approximately six times higher 
among women compared with men for both physician- (p<0.001) and rheumatologist-
diagnosed pSS (p<0.001). Trends in both physician- and rheumatologist-diagnosed pSS 
were similar to incidence. The age-adjusted prevalence of physician-diagnosed pSS 
was 23.8 among White women, 23.7 among Asian women, 16.1 among Black women, 
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and 15.0 among Latina women. For rheumatologist-diagnosed pSS, Asian women had 
the highest rate, followed by White, Black, and Latina women. However, there were no 
significant differences in physician- or rheumatologist-diagnosed prevalence rates by 
race/ethnicity overall, among women, or among men.  
Capture-recapture estimated an additional 24.2 cases of physician-diagnosed pSS, 
indicating that 12.7% of cases may have been missed. Among cases missed, almost 
two-thirds (65.3%) were White women. With capture-recapture adjustment, the overall 
prevalence by physician diagnosis increased to 14.2 per 100,000 person-years (95% CI 
12.3-16.1).  
The average ages (± SD) among women and men with pSS identified by physician 
diagnosis were 56.4 (± 17.5) and 60.9 (± 16.9) years respectively. The average age of 
physician-diagnosed pSS in 2007 was 60.3 (± 16.7) years among Whites, 53.1 (± 20.5) 
years among Blacks, 52.9 (± 14.8) years among Latinos, and 49.6 (± 19.6) years 
among Asians.  
Among physician- and rheumatologist-diagnosed prevalent Latino cases, more than 
three-quarters were also identified as White. Information on Latino ethnicity was often 
absent, with more than two-thirds having no further details. Among Asian pSS cases 
diagnosed by a physician or rheumatologist, more than a quarter had no further 
classification for Asian ethnicity.  
Table 4 shows the occurrence of relevant serologic and clinical manifestations captured 
in the MLSP for prevalent physician- and rheumatologist-diagnosed pSS cases. Similar 
to incident cases, data ascertainment on manifestations was more complete for cases 
with a rheumatologist diagnosis.   
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Incidence and Prevalence of pSS using Modified Criteria  
Using the modified case definition of pSS (Table 5), incorporating the presence of 
autoantibodies and documentation of dry eyes and/or dry mouth resulted in an overall 
age-adjusted incidence rate of 1.1 (95% CI 0.8-1.5) per 100,000 person-years and an 
overall age-adjusted prevalence rate of 3.3 (95% CI 2.4-4.4) per 100,000 person-years. 
As with the other case definitions, age-adjusted rates were higher among women 
compared with men (p<0.001). Incidence rates differed by race/ethnicity overall 
(p<0.001), with higher rates among Asians compared with Whites (p=0.007) and Latinos 
(p=0.005), and among women (p<0.001), with higher rates among Asians compared 
with Blacks (p=0.003). Prevalence of pSS differed by race/ethnicity overall (p=0.001) 
and among women (p<0.001) but no significant differences were found by pairwise 
comparison.  
Incident and Prevalent Cases of pSS Meeting Criteria for SLE 
Cases with a diagnosis of pSS also met ≥4 of the ACR and/or SLICC criteria for SLE 
despite not being clinically diagnosed as SLE (Table 6). Depending on the case 
definition for pSS, 4.3-10.2% of incident cases met the ACR criteria for SLE and 5.8-
16.3% met the SLICC criteria. The modified case definition for pSS had the highest 
percentage of incident cases meeting ACR and SLICC criteria for SLE. There was a 
higher percentage of prevalent pSS cases meeting SLE criteria (ACR: 6.6-14.9%; 
SLICC: 14.5-34.0%).  
Discussion  
Our analysis of the MLSP dataset provides incidence and prevalence rate estimates of 
pSS among Manhattan residents. These data also provided epidemiologic estimates for 
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the major racial/ethnic populations in the US. The age-standardized incidence and 
prevalence of physician-diagnosed pSS in Manhattan were 3.5 (95% CI 2.9-4.1) and 
13.1 (95% CI 11.1-15.1) per 100,000 person-years. Capture-recapture adjustment 
increased incidence and prevalence rates by 17.2% and 12.7%, respectively. By 
rheumatologist diagnosis, the age-adjusted incidence and prevalence of pSS were 2.1 
(95% CI 1.7-2.6) and 7.3 (95% CI 5.9-8.9). Incidence was highest among Asians and 
Whites, though prevalence did not significantly differ by race/ethnicity, and there were 
substantial disparities in the prevalence and incidence of pSS among Manhattan 
residents by sex. This analysis also provides information on serologic and clinical 
manifestations among pSS cases including data on extraglandular manifestations. In 
addition, these data reveal that up to a third of prevalent cases diagnosed with pSS also 
fulfill both ACR and SLICC criteria for SLE, even though they do not carry a diagnosis of 
SLE, reflecting commonalities in manifestations of the two diseases. Not surprisingly, 
these data suggest that in clinical practice physicians diagnose patients without formal 
application of disease criteria.     
Previous studies on the epidemiology of SS span decades, come from different regions 
of the world, and have used varying methods of case identification (2, 3). The few 
published estimates for the general population reveal annual incidence rates of 6.9–
20.1 per 100,000 persons (3) and markedly discrepant prevalence figures ranging from 
11.3–3790.1 cases per 100,000 persons (3). Whether these estimates reflect genuine 
variability between different populations or differences in methodology and study design 
is unclear.  
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Existing data suggests the disease is most common in middle-aged women, which is 
consistent with findings of our analysis (2, 3). In line with these findings, our analyses 
were restricted to adults aged ≥18 years though it is worth noting that the MLSP did 
identify pediatric cases of pSS. However, including these pediatric cases into our 
prevalence and incidence estimates of physician-diagnosed pSS would have decreased 
our estimates by at least 21% given the small number of cases added to our numerator 
relative to the person-years added to our denominator.  
In a meta-analysis of pSS studies published to date (3), 21 population-based studies 
were identified, of which only 10 included a review of medical records; the rest were 
population-based surveys. Six studies (20-25) determined an incidence rate, only one of 
which was US-based (21); the authors calculated a pooled pSS prevalence rate of 60.8 
per 100,000 person-years and an incidence rate of 6.9 per 100,000, both higher than 
our estimates. However, in line with the findings from our study, the authors found a 
higher pooled pSS incidence rate among women compared with men (12.3 vs. 1.5). A 
report limited to European-based studies using the AECG criteria for pSS showed a 
European prevalence of pSS at 38.95 per 100,000 population (26),  and after being 
updated as a meta-analysis showed a point prevalence of 4.7 per 10,000 population 
(27).    
A recent US-based study of pSS was conducted in Olmsted County, MN, with a mostly 
White population and reported a population-based prevalence estimate for pSS based 
on physician diagnosis of 10.3 per 10,000 residents, again higher than our estimate. 
Even using the conservative AECG definition, the prevalence estimate was still higher 
than ours at 2.2 (95%CI:1.3–3.1) per 10,000 (28). A separate study of the same 
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population also provided a higher annual incidence rate of physician-diagnosed pSS at 
5.9 per 100,000 population (95%CI:4.4-7.4) (29).  
There are virtually no studies that present pSS findings among diverse populations. The 
meta-analysis (3) presented no information on race or ethnicity other than a few studies 
done in Taiwan (23-25) which found a pooled incidence rate of 6.6 per 100,000 with 
significant heterogeneity. One study conducted in the greater Paris area of France 
reported population-based estimates of pSS prevalence among a multi-racial/multi-
ethnic population (2). In line with our findings, prevalence estimates of pSS in this study 
ranged from 10.0 per 100,000 adults aged ≥15 years to 15.2 per 100,000, depending on 
the definition used. Prevalence was approximately two times higher for non-Europeans, 
though incidence and further breakdown on non-European origin was not reported (2). 
Our study did not find significant differences in prevalence by race/ethnicity but also had 
a different racial/ethnic makeup. However, we did find significant differences in 
incidence by race/ethnicity.  
There were several limitations regarding the development of the MLSP previously 
acknowledged (4). These analyses may have underestimated incident and prevalent 
cases as two hospitals and one quarter of rheumatologists in the catchment area, who 
practiced in predominantly White neighborhoods, declined to participate.  Given that the 
Veteran’s Administration Hospital was one of the hospitals that declined to participate 
(the other was a cancer specialty hospital), we may have specifically under-identified 
males diagnosed with pSS. It is also possible that cases were missed if they lived in 
Manhattan but sought care in other boroughs or a neighboring state. We also did not 
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include ophthalmologists, otolaryngologists, or primary care practices among our case 
finding sources.  
As previously detailed (4), additional limitations of the MLSP resulted from the 
tremendous differences across medical systems and abstracting several years after the 
surveillance period. These limitations could have resulted in abstractors missing 
information such as results of minor salivary gland biopsies and objective results of 
ocular and oral tests. This could account for our rates using the modified case definition 
(16) being considerably lower than those by physician and rheumatologist diagnosis.  
Another explanation for these lower rates using the modified case definition comes from 
feedback obtained from our abstractors while in the field. Documentation of salivary 
gland biopsies or objective evidence of dry eyes (positive Schirmer's test, rose bengal 
score, or other ocular dye score), dry mouth (positive unstimulated whole salivary flow 
test, parotid sialography, or salivary scintigraphy), and lip biopsies were rare which 
limited our planned ability to use the various pSS criteria (13, 15, 16). In addition when 
biopsies were performed they were not reported in any standardized way (30).  
This observation was corroborated in a recent article exploring the prevalence of SS in 
Olmsted County, MN, where the rates for AECG confirmed SS were considerably lower 
than rates for physician-diagnosed SS (28). The authors concluded that classification 
criteria do not accurately reflect the diagnosis of SS in clinical practice in part because 
the criteria include invasive tests that are rarely performed in routine care (28). 
Importantly, these criteria sets were not developed for diagnostic use in routine clinical 
practice, but were designed to capture a more homogeneous patient population for the 
purpose of research and clinical trials (31). 
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Additional limitations pertain to assigning race and ethnicity based on administrative and 
medical records. Though available information did reflect the major ethnic subgroups in 
Manhattan, specific ethnicity information was missing for most Latino cases and more 
than one quarter of Asian cases. Categorized broadly, Latino or Asian race 
encompasses a number of heterogeneous groups and pSS rates among them may 
differ. Given the already limited number of published studies on pSS among Asians and 
Latinos, additional work is needed to better describe and understand the epidemiology 
of pSS among specific ethnic subpopulations. 
Despite these limitations, our analysis benefitted from the design and composition of the 
MLSP (4). First, the MLSP was designed as a population-based registry with a diverse 
population, which allowed us to estimate rates of pSS among the major racial/ethnic 
categories. The partnership with the DOHMH allowed us to collect information from a 
number of case finding sources, which facilitated more complete clinical information on 
many cases. In addition, we conducted capture-recapture analyses to estimate missed 
cases. Finally, our abstractors all had medical backgrounds, which helped during 
training and provided an advantage during extensive review of medical records to 
identify criteria and manifestations of pSS. 
In conclusion, data from a large population-based registry revealed substantial 
disparities by sex in pSS among Manhattan residents. Differences were also found in 
the incidence of pSS by race/ethnicity, highlighting higher rates among Asian women 
which have not been documented previously in the US.  
Funding: This work was supported by cooperative agreements between the Centers for 
Disease Control and Prevention and The New York City Department of Health and 
20 
 
Mental Hygiene [grant number U58/DP002827] and a cooperative agreement between 
the New York City Department of Health and Mental Hygiene and New York University 
School of Medicine. 
Acknowledgements: 
The authors would like to acknowledge Benjamin Wainwright for assistance in preparing 
the manuscript. The authors wish to thank all of the rheumatologists and their practice 
managers who participated in the MLSP. We would also like to thank all the 
administrators in the medical records departments of the hospitals who participated in 
the MLSP for their assistance obtaining medical records. At the DOHMH, the MLSP 
would like to acknowledge the contributions of past and current members including 
Tamira Collins-Bowers, Manasi Joshi, Bonnie Kerker, Maushumi Mavinkurve, Angela 
Merges, Kyyon Nelson, Viren Shah, Joseph Slade, Lorna Thorpe, Talytha Utley, and 
Elizabeth Waddell. In addition, the MLSP would like to acknowledge the hard work of 
their abstractors Drs. Janice McFarlane, Nick Stefanopoulos, Zahira Zahid, Rukayatu 
Ibrahim, Saleh Massasati, and Simone Shrestha. Finally we would like to acknowledge 
the support and contribution of the of the principal investigators of the other CDC-
funded surveillance sites including Drs. Sam Lim, Cristina Drenkard, Emily Somers, Joe 
McCune, Maria Dall’Era, and Elizabeth Ferucci. 
  
21 
 
References 
1. Brito-Zeron P, Baldini C, Bootsma H, Bowman SJ, Jonsson R, Mariette X, et al. 
Sjogren syndrome. Nat Rev Dis Primers. 2016;2:16047. 
2. Maldini C, Seror R, Fain O, Dhote R, Amoura Z, De Bandt M, et al. Epidemiology 
of primary Sjogren's syndrome in a French multiracial/multiethnic area. Arthritis Care 
Res (Hoboken). 2014;66(3):454-63. 
3. Qin B, Wang J, Yang Z, Yang M, Ma N, Huang F, et al. Epidemiology of primary 
Sjogren's syndrome: a systematic review and meta-analysis. Ann Rheum Dis. 
2015;74(11):1983-9. 
4. Izmirly PM, Wan I, Sahl S, Buyon JP, Belmont HM, Salmon JE, et al. The 
Incidence and Prevalence of Systemic Lupus Erythematosus in New York County 
(Manhattan), New York: The Manhattan Lupus Surveillance Program. Arthritis 
Rheumatol. 2017;69(10):2006-17. 
5. Lim SS, Bayakly AR, Helmick CG, Gordon C, Easley KA, Drenkard C. The 
incidence and prevalence of systemic lupus erythematosus, 2002-2004: The Georgia 
Lupus Registry. Arthritis Rheumatol. 2014;66(2):357-68. 
6. Somers EC, Marder W, Cagnoli P, Lewis EE, DeGuire P, Gordon C, et al. 
Population-based incidence and prevalence of systemic lupus erythematosus: the 
Michigan Lupus Epidemiology and Surveillance program. Arthritis Rheumatol. 
2014;66(2):369-78. 
7. Ferucci ED, Johnston JM, Gaddy JR, Sumner L, Posever JO, Choromanski TL, 
et al. Prevalence and incidence of systemic lupus erythematosus in a population-based 
registry of American Indian and Alaska Native people, 2007-2009. Arthritis Rheumatol. 
2014;66(9):2494-502. 
8. Dall'Era M, Cisternas MG, Snipes K, Herrinton LJ, Gordon C, Helmick CG. The 
Incidence and Prevalence of Systemic Lupus Erythematosus in San Francisco County, 
California: The California Lupus Surveillance Project. Arthritis Rheumatol. 
2017;69(10):1996-2005. 
9. New York City Department of Health and Mental Hygiene. Epiquery: NYC 
Interactive Health Data System - NYCDOHMH neighborhood population estimates, 
modified from the US Census Bureau vintage population estimates, 2007, 2008, 2009. 
2016. 
10. Hochberg MC. Updating the American College of Rheumatology revised criteria 
for the classification of systemic lupus erythematosus. Arthritis Rheum. 
1997;40(9):1725. 
11. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 
1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis 
Rheum. 1982;25(11):1271-7. 
12. Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation 
and validation of the Systemic Lupus International Collaborating Clinics classification 
criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-86. 
13. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons 
SE, et al. Classification criteria for Sjogren's syndrome: a revised version of the 
European criteria proposed by the American-European Consensus Group. Ann Rheum 
Dis. 2002;61(6):554-8. 
22 
 
14. Lieberman SM. Childhood Sjogren syndrome: insights from adults and animal 
models. Curr Opin Rheumatol. 2013;25(5):651-7. 
15. Shiboski SC, Shiboski CH, Criswell L, Baer A, Challacombe S, Lanfranchi H, et 
al. American College of Rheumatology classification criteria for Sjogren's syndrome: a 
data-driven, expert consensus approach in the Sjogren's International Collaborative 
Clinical Alliance cohort. Arthritis Care Res (Hoboken). 2012;64(4):475-87. 
16. Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al. 
2016 American College of Rheumatology/European League Against Rheumatism 
classification criteria for primary Sjogren's syndrome: A consensus and data-driven 
methodology involving three international patient cohorts. Ann Rheum Dis. 
2017;76(1):9-16. 
17. Klein RJ, Schoenborn CA. Age adjustment using the 2000 projected U.S. 
population. Healthy People 2010 Stat Notes. 2001(20):1-10. 
18. Hook EB, Regal RR. Capture-recapture methods in epidemiology: methods and 
limitations. Epidemiol Rev. 1995;17(2):243-64. 
19. Baillargeon S, Rivest L. Rcapture: Loglinear Models for Capture-Recapture in R. 
J Stat Softw. 2007;19(5):1-31. 
20. Alamanos Y, Tsifetaki N, Voulgari PV, Venetsanopoulou AI, Siozos C, Drosos 
AA. Epidemiology of primary Sjogren's syndrome in north-west Greece, 1982-2003. 
Rheumatology (Oxford). 2006;45(2):187-91. 
21. Pillemer SR, Matteson EL, Jacobsson LT, Martens PB, Melton LJ, 3rd, O'Fallon 
WM, et al. Incidence of physician-diagnosed primary Sjogren syndrome in residents of 
Olmsted County, Minnesota. Mayo Clin Proc. 2001;76(6):593-9. 
22. Plesivcnik Novljan M, Rozman B, Hocevar A, Grmek M, Kveder T, Tomsic M. 
Incidence of primary Sjogren's syndrome in Slovenia. Ann Rheum Dis. 2004;63(7):874-
6. 
23. See LC, Kuo CF, Chou IJ, Chiou MJ, Yu KH. Sex- and age-specific incidence of 
autoimmune rheumatic diseases in the Chinese population: a Taiwan population-based 
study. Semin Arthritis Rheum. 2013;43(3):381-6. 
24. Weng MY, Huang YT, Liu MF, Lu TH. Incidence and mortality of treated primary 
Sjogren's syndrome in Taiwan: a population-based study. J Rheumatol. 2011;38(4):706-
8. 
25. Yu KH, See LC, Kuo CF, Chou IJ, Chou MJ. Prevalence and incidence in 
patients with autoimmune rheumatic diseases: a nationwide population-based study in 
Taiwan. Arthritis Care Res (Hoboken). 2013;65(2):244-50. 
26. Cornec D, Chiche L. Is primary Sjogren's syndrome an orphan disease? A critical 
appraisal of prevalence studies in Europe. Ann Rheum Dis. 2015;74(3):e25. 
27. Nocturne G, Seror R, Mariette X, Devauchelle-Pensec V, Saraux A, Chiche L. 
Primary Sjogren's Syndrome Prevalence: What if Sjogren was Right After All? Comment 
on the Article by Maciel et al. Arthritis Care Res (Hoboken). 2018;70(6):951-3. 
28. Maciel G, Crowson CS, Matteson EL, Cornec D. Prevalence of Primary Sjogren's 
Syndrome in a US Population-Based Cohort. Arthritis Care Res (Hoboken). 
2017;69(10):1612-6. 
29. Maciel G, Crowson CS, Matteson EL, Cornec D. Incidence and Mortality of 
Physician-Diagnosed Primary Sjogren Syndrome: Time Trends Over a 40-Year Period 
in a Population-Based US Cohort. Mayo Clin Proc. 2017;92(5):734-43. 
23 
 
30. Fisher BA, Jonsson R, Daniels T, Bombardieri M, Brown RM, Morgan P, et al. 
Standardisation of labial salivary gland histopathology in clinical trials in primary 
Sjogren's syndrome. Ann Rheum Dis. 2017;76(7):1161-8. 
31. Vitali C, Del Papa N. Classification and diagnostic criteria in Sjogren's syndrome: 
a long-standing and still open controversy. Ann Rheum Dis. 2017;76(12):1953-4. 
 
  
24 
 
Table 1: Crude and age-adjusted incidence rates of Sjögren's Syndrome among 
Manhattan residents aged 18 and older, 2007-2009, overall and by race/ethnicity and 
sex 
     Capture-Recapture  
 Crude rate 
(95% CI) 
Age-adjusted rate 
(95% CI) 
χ2 p-value N  
missed 
Rate (95% CI) 
Primary Sjögren's with Physician Diagnosis 
Total 3.4 (2.9-4.0) 3.5 (2.9-4.1) <0.001 28.7 4.1 (2.5-5.8) 
Male 0.9 (0.5-1.5) 1.0 (0.6-1.5)  4.7 1.2 (0.2-2.1) 
Female 5.6 (4.6-6.6) 5.7 (4.7-6.7)  24.0 6.7 (4.3-9.1) 
Race/ethnicity    <0.001 1   
Non-Latino 
White 
3.7 (3.0-4.7) 3.8 (3.0-4.7)  21.2 4.8 (2.2-7.4) 
Non-Latino 
Black 
2.2 (1.1-3.9) 2.2 (1.1-4.0)  1.1 2.4 (1.4-3.4) 
Latino 1.9 (1.1-3.0) 2.0 (1.2-3.2)  1.7 2.1 (1.7-2.5) 
Non-Latino 
Asian 
5.6 (3.6-8.1) 6.2 (4.0-9.2)  4.3 6.5 (5.2-7.8) 
Non-Latino 
Other 
-   0.4  
 
Race/ethnicity by sex 
Male    0.859   
Non-Latino 
White 
1.1 (0.6-2.0) 1.1 (0.5-2.0)  4.3 1.6 (0.1-3.1) 
Non-Latino 
Black 
0.9 (0.1-3.2) 0.9 (0.1-3.2)  0.2 1.0 (0.3-1.7) 
Latino 0.5 (0.1-1.7) 0.5 (0.1-1.7)  0.2 0.5 (0.1-0.9) 
Non-Latino 
Asian 
0.5 (0.0-2.7) 0.6 (0.0-3.6)  0.0 0.5 (0.4-0.6) 
Female    <0.001 2   
Non-Latina 
White 
6.1 (4.7-7.8) 6.2 (4.7-7.9)  16.9 7.7 (4.1-11.3) 
Non-Latina 
Black 
3.2 (1.5-6.1) 3.3 (1.5-6.3)  0.9 3.5 (2.3-4.8) 
Latina 3.2 (1.8-5.1) 3.2 (1.8-5.2)  1.5 3.5 (3.1-3.8) 
Non-Latina 
Asian 
9.5 (6.2-14.0) 10.5 (6.6-15.7)  4.3 11.1 (8.9-13.4) 
 
Primary Sjögren's with Rheumatologist Diagnosis 
Total 2.1 (1.7-2.6) 2.1 (1.7-2.6) <0.001 34.0 2.9 (1.1-4.8) 
Male 0.5 (0.2-0.9) 0.5 (0.2-0.9)    
Female 3.5 (2.7-4.4) 3.5 (2.7-4.4)    
Race/ethnicity    0.001 1   
Non-Latino 
White 
2.4 (1.8-3.2) 2.3 (1.7-3.1)  13.2 3.0 (2.1-4.0) 
Non-Latino 
Black 
1.2 (0.4-2.6) 1.2 (0.5-2.7)  9.0 2.9 (-1.8-7.7) 
Latino 1.0 (0.4-1.8) 0.9 (0.4-1.8)  0.6 1.0 (0.6-1.5) 
Non-Latino 
Asian 
3.8 (2.3-6.1) 4.1 (2.3-6.5)  10.7 6.1 (1.0-11.2) 
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Non-Latino 
Other 
-   0.5  
 
Race/ethnicity by sex 
Male    0.524   
Non-Latino 
White 
0.6 (0.2-1.3) 0.5 (0.2-1.2)    
Non-Latino 
Black 
0.9 (0.1-3.2) 0.9 (0.1-3.2)    
Latino -     
Non-Latino 
Asian 
0.5 (0.0-2.7) 0.6 (0.0-3.6)    
Female    0.001 3   
Non-Latina 
White 
4.0 (2.9-5.4) 3.8 (2.8-5.2)    
Non-Latina 
Black 
1.4 (0.4-3.6) 1.6 (0.4-4.1)    
Latina 1.8 (0.8-3.4) 1.7 (0.8-3.3)    
Non-Latina 
Asian 
6.5 (3.8-10.3) 6.7 (3.8-11.1)    
Rates are per 100,000 Manhattan residents. Denominator data is based on 2007-2009 intercensal 
population estimates from the NYC DOHMH Bureau of Epi Services (2000-2014 files). 
Data are age adjusted to the US2000 Standard Population. 
Cases were assigned to one of five mutually exclusive race/ethnicity categories: non-Latino white, non-
Latino black, non-Latino Asian, Latino, and non-Latino other. Non-Latino cases identified with more than 
one race were categorized as non-Latino other. 
For capture-recapture analyses, log-linear models were fit separately for by sex and race/ethnicity for 
physician diagnosed cases and by sex alone for cases diagnosed by rheumatologist or meeting the 
modified case definition. 
1 Latinos differed from non-Latino Whites and non-Latino Asians. Non-Latino Asians also differed from 
non-Latino Blacks. 
2 Latinas differed from non-Latina Whites and non-Latina Asians. Non-Latina Asians also differed from 
non-Latina Blacks. 
3 Latinas differed from non-Latina Whites and non-Latina Asians. Non-Latina Blacks also differed from 
non-Latina Whites and non-Latina Asians. 
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Table 2: Frequency of specific manifestations among incident Sjögren's Syndrome 
cases among NYC Manhattan residents aged 18 and older, 2007-2009 
  Primary Sjogren's with 
Physician Diagnosis 
Primary Sjogren's with 
Rheumatologist 
Diagnosis 
Primary Sjogren's - 
modified definition   
  
Number  
available 
Positive Number  
available 
Positive Number  
available 
Positive 
N % N % N % 
Overall N 138    84    45    
                 
Glandular/serologies          
Sicca symptoms 122 91 74.6% 82 72 87.8% 45 45 100.0% 
Anti-SSA/Ro 96 63 65.6% 78 52 66.7% 45 45 100.0% 
Anti-SSB/La 90 37 41.1% 75 30 40.0% 42 23 55.0% 
Anti-SSA/Ro and Anti-
SSB/La 
 
90 33 36.7% 75 26 34.7% 42 23 55.0% 
ANA  90 71 78.9% 72 61 84.7% 39 37 95.0% 
ANA titer >1:320 45 30 66.7% 39 25 64.1% 25 16 64.0% 
Rheumatoid factor 67 27 40.3% 53 22 41.5% 31 17 55.0% 
                 
Extraglandular          
Arthritis 137 29 21.2% 83 19 22.9% 44 10 23.0% 
Photo sensitivity 138 7 5.1% 84 7 8.3% 45 4 9.0% 
Lymphopenia 124 64 51.6% 79 39 49.4% 42 22 52.0% 
Interstitial lung 
disease 
138 4 2.9% 84 2 2.4% 45 2 4.0% 
Pneumonitis 138 1 0.7% 84 1 1.2% 45 1 2.0% 
Transverse myelitis 138 0 0.0% 84 0 0.0% 45 0 0.0% 
Low complements 138 5 3.6% 84 5 6.0% 45 5 11.0% 
Raynaud's 138 13 9.4% 84 9 10.7% 45 3 7.0% 
Cutaneous vasculitis  138 0 0.0% 84 0 0.0% 45 0 0.0% 
Cranial or peripheral 
neuropathy 
137 10 7.3% 84 5 6.0% 45 2 4.0% 
Myositis  137 0 0.0% 83 0 0.0% 44 0 0.0% 
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Table 3: Crude and age-adjusted prevalence rates of Sjögren's Syndrome among 
Manhattan residents aged 18 and older, 2007, overall and by race/ethnicity and sex 
     Capture-Recapture  
  Crude rate  
(95% CI) 
Age-adjusted rate 
(95% CI) 
χ2 p-
value 
N  
missed 
Rate (95% CI) 
Primary Sjögren's with Physician Diagnosis 
Total 12.4 (10.5-14.3) 13.1 (11.1-15.1) <0.001 24.2 14.2 (12.3-16.1) 
Male 3.1 (1.9-4.8) 3.5 (2.1-5.5)  0.1 3.1 (3.0-3.2) 
Female 20.5 (17.2-23.8) 21.1 (17.6-24.5)  24.1 23.9 (20.3-27.4) 
Race/ethnicity    0.099   
Non-Latino 
White 
13.9 (11.3-17.0) 14.6 (11.8-17.9)  15.9 16.3 (14.4-18.1) 
Non-Latino 
Black 
9.4 (5.4-15.2) 9.4 (5.4-15.4)  0.5 9.6 (8.4-10.9) 
Latino 8.6 (5.7-12.6) 9.1 (6.0-13.2)  0.6 8.8 (8.1-9.5) 
Non-Latino 
Asian 
13.1 (8.0-20.2) 14.3 (8.5-22.5)  6.1 17.1 (11.6-22.6) 
Non-Latino 
Other 
    1.1  
 
Race/ethnicity by sex 
Male    0.638   
Non-Latino 
White 
4.0 (2.1-6.9) 4.3 (2.3-7.4)  0.1 4.0 (3.8-4.3) 
Non-Latino 
Black 
1.3 (0.0-7.3) 1.7 (0.0-9.4)  0.0 1.3 (1.3-1.3) 
Latino 1.4 (0.2-5.0) 1.5 (0.2-5.4)  0.0 1.4 (1.4-1.4) 
Non-Latino 
Asian 
1.5 (0.0-8.3) 2.2 (0.1-12.5)  0.0 1.5 (1.5-1.5) 
Female    0.153   
Non-Latina 
White 
22.9 (18.2-28.4) 23.8 (18.9-29.6)  15.8 27.3 (24.0-30.7) 
Non-Latina 
Black 
15.8 (8.9-26.1) 16.1 (8.9-26.7)  0.5 16.3 (14.1-18.6) 
Latina 14.9 (9.6-21.9) 15.0 (9.7-22.2)  0.6 15.2 (13.9-16.5) 
Non-Latina 
Asian 
22.2 (13.4-34.6) 23.7 (13.9-37.7)  6.1 29.3 (19.5-39.1) 
            
Primary Sjögren's with Rheumatologist Diagnosis 
Total 7.0 (5.7-8.6) 7.3 (5.9-8.9) <0.001 27.3 9.1 (6.2-11.9) 
Male 1.6 (0.8-3.0) 1.8 (0.9-3.4)    
Female 11.7 (9.3-14.5) 11.9 (9.5-14.8)    
Race/ethnicity    0.399   
Non-Latino 
White 
7.2 (5.3-9.5) 7.5 (5.5-10.0)  17.5 9.7 (7.5-12.0) 
Non-Latino 
Black 
5.3 (2.4-10.0) 5.6 (2.5-10.6)  1.3 6.0 (4.2-7.9) 
Latino 5.4 (3.2-8.7) 5.6 (3.2-9.0)  2.0 6.1 (5.0-7.2) 
Non-Latino 
Asian 
9.2 (5.0-15.4) 9.7 (5.1-16.6)  3.6 11.5 (5.5-17.5) 
Non-Latino 
Other 
    2.9  
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Race/ethnicity by sex 
Male    0.703   
Non-Latino 
White 
2.2 (0.9-4.5) 2.4 (0.9-4.9)    
Non-Latino 
Black 
-     
Latino 0.7 (0.0-3.9) 0.8 (0.0-4.3)    
Non-Latino 
Asian 
1.5 (0.0-8.3) 2.2 (0.1-12.5)    
Female    0.490   
Non-Latina 
White 
11.7 (8.5-15.9) 12.1 (8.7-16.5)    
Non-Latina 
Black 
9.5 (4.3-18.0) 10.4 (4.7-19.8)    
Latina 9.5 (5.4-15.4) 9.4 (5.4-15.3)    
Non-Latina 
Asian 
15.2 (8.1-25.9) 15.6 (8.0-27.3)    
Rates are per 100,000 Manhattan residents. Denominator data is based on 2007-2009 intercensal 
population estimates from the NYC DOHMH Bureau of Epi Services (2000-2014 files) 
Data are age adjusted to the US2000 Standard Population. 
Cases were assigned to one of five mutually exclusive race/ethnicity categories: non-Latino white, non-
Latino black, non-Latino Asian, Latino, and non-Latino other. Non-Latino cases identified with more than 
one race were categorized as non-Latino other. 
For capture-recapture analyses, log-linear models were fit separately for by sex and race/ethnicity for 
physician diagnosed cases and by sex alone for cases diagnosed by rheumatologist or meeting the 
modified case definition.           
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Table 4: Frequency of specific manifestations among prevalent Sjögren's Syndrome 
cases among NYC Manhattan residents aged 18 and older, 2007 
  Primary Sjögren's with 
Physician Diagnosis 
Primary Sjögren's with 
Rheumatologist 
Diagnosis 
Primary Sjögren's - 
modified definition   
  
Number  
available 
Positive Number  
available 
Positive Number  
available 
Positive 
N % N % N % 
Overall N 166    94    47    
                 
Glandular/serologies          
Sicca symptoms 152 110 72.4% 91 81 89.0% 44 44 100.0% 
Anti-SSA/Ro 
 
102 60 58.8% 77 48 62.3% 44 44 100.0% 
Anti-SSB/La 
 
100 47 47.0% 77 37 48.1% 44 32 73.0% 
Anti-SSA/Ro and Anti-
SSB/La 
 
100 44 44.0% 77 34 44.2% 44 32 73.0% 
ANA  106 72 67.9% 81 58 71.6% 44 38 86.0% 
ANA titer >1:320 56 32 57.1% 46 27 58.7% 31 21 68.0% 
Rheumatoid factor 82 42 51.2% 64 36 56.3% 35 26 74.0% 
                 
Extraglandular          
Arthritis 166 37 22.3% 94 26 27.7% 44 16 36.0% 
Photo sensitivity 166 5 3.0% 94 5 5.3% 44 3 7.0% 
Lymphopenia 149 103 69.1% 87 61 70.1% 44 35 80.0% 
Interstitial lung disease 166 10 6.0% 94 5 5.3% 44 3 7.0% 
Pneumonitis 166 3 1.8% 94 1 1.1% 44 1 2.0% 
Transverse myelitis 166 0 0.0% 94 0 0.0% 44 0 0.0% 
Low complements 166 10 6.0% 94 10 10.6% 44 7 16.0% 
Raynaud's 166 16 9.6% 94 14 14.9% 44 5 11.0% 
Cutaneous vasculitis  166 6 3.6% 94 3 3.2% 44 2 5.0% 
Cranial or peripheral 
neuropathy 
165 17 10.3% 94 12 12.8% 44 5 11.0% 
Myositis  166 2 1.2% 94 1 1.1% 44 1 2.0% 
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Table 5: Crude and age-adjusted rates of Primary Sjögren's Syndrome by Modified 
Definition among Manhattan residents aged 18 and older, overall and by 
race/ethnicity and sex 
     Capture-Recapture  
  Crude rate 
(95% CI) 
Age-adjusted rate 
(95% CI) 
χ2 p-
value 
N  
missed 
Rate (95% CI) 
Incidence, 2007-2009 
Total 1.1 (0.8-1.5) 1.1 (0.8-1.5) <0.001 14.1 1.5 (0.3-2.6) 
Male 0.2 (0.1-0.6) 0.2 (0.1-0.5)    
Female 1.9 (1.4-2.6) 1.8 (1.3-2.5)    
Race/ethnicity    <0.001 1   
Non-Latino 
White 
0.9 (0.6-1.4) 0.9 (0.5-1.3)  2.0 1.0 (0.6-1.4) 
Non-Latino 
Black 
0.8 (0.2-2.0) 0.8 (0.2-2.1)  2.4 1.3 (-1.1-3.6) 
Latino 0.7 (0.3-1.5) 0.7 (0.3-1.5)  1.2 0.9 (0.2-1.5) 
Non-Latino 
Asian 
3.0 (1.6-5.0) 3.3 (1.6-5.2)  8.2 4.7 (0.8-8.7) 
Non-Latino 
Other 
-   0.3  
 
Race/ethnicity by sex 
Male    0.004   
Non-Latino 
White 
0.1 (0.0-0.6) 0.1 (0.0-0.5)    
Non-Latino 
Black 
0.9 (0.1-3.2) 0.9 (0.1-3.2)    
Latino -     
Non-Latino 
Asian 
0.5 (0.0-2.7) 0.6 (0.0-3.6)    
Female    <0.001 2   
Non-Latina 
White 
1.7 (1.0-2.6) 1.5 (0.9-2.3)    
Non-Latina 
Black 
0.7 (0.1-2.6) 0.7 (0.1-2.7)    
Latina 1.4 (0.6-2.8) 1.4 (0.5-2.8)    
Non-Latina 
Asian 
4.9 (2.6-8.5) 4.9 (2.5-8.6)    
            
Prevalence, 2007 
Total 3.3 (2.4-4.4) 3.3 (2.4-4.4) <0.001 18.6 4.7 (1.4-8.0) 
Male 0.5 (0.1-1.4) 0.5 (0.1-1.4)    
Female 5.7 (4.1-7.8) 5.7 (4.1-7.8)    
Race/ethnicity    0.001   
Non-Latino 
White 
2.8 (1.7-4.4) 2.8 (1.6-4.3)  12.3 4.6 (0.6-8.6) 
Non-Latino 
Black 
3.5 (1.3-7.6) 3.6 (1.3-7.8)  0.8 4.0 (2.6-5.3) 
31 
 
Latino 3.2 (1.5-5.9) 3.1 (1.5-5.7)  2.5 4.0 (2.4-5.6) 
Non-Latino 
Asian 
5.2 (2.3-10.3) 5.2 (2.1-10.5)  2.1 6.6 (3.0-10.2) 
Non-Latino 
Other 
-   0.9  
 
Race/ethnicity by sex  
Male       
Non-Latino 
White 
0.9 (0.2-2.7) 0.9 (0.2-2.8)    
Non-Latino 
Black 
-     
Latino -     
Non-Latino 
Asian 
     
Female    0.001   
Non-Latina 
White 
4.5 (2.6-7.3) 4.8 (2.5-7.2)    
Non-Latina 
Black 
6.3 (2.3-13.8) 6.6 (2.4-14.5)    
Latina 5.9 (2.9-10.9) 5.8 (2.7-10.7)    
Non-Latina 
Asian 
9.3 (4.0-18.4) 9.4 (3.9-19.1)    
Rates are per 100,000 Manhattan residents. Denominator data is based on 2007-2009 intercensal 
population estimates from the NYC DOHMH Bureau of Epi Services (2000-2014 files). 
Data are age adjusted to the US2000 Standard Population. 
Cases were assigned to one of five mutually exclusive race/ethnicity categories: non-Latino white, non-
Latino black, non-Latino Asian, Latino, and non-Latino other. Non-Latino cases identified with more than 
one race were categorized as non-Latino other. 
For capture-recapture analyses, log-linear models were fit separately for by sex and race/ethnicity for 
physician diagnosed cases and by sex alone for cases diagnosed by rheumatologist or meeting the 
modified case definition. 
1 Non-Latino Asians differed from non-Latino Whites and Latinos. 
2 Non-Latina Asians differed from non-Latina Blacks. 
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Table 6: Frequency of specific manifestations among primary Sjögren's 
Syndrome cases among NYC Manhattan residents aged 18 and older 
  Incident cases, 2007-2009 
  Physician Diagnosis Rheumatologist 
Diagnosis 
Modified Definition 
  N % 
positive 
N % 
positive 
N % 
positive 
Overall N 138  84  49  
Meet ACR SLE 
criteria 
  4.3%  7.1%  10.2% 
Meet SLICC SLE 
criteria 
  5.8%  9.5%  16.3% 
              
  Prevalent cases, 2007 
  Physician Diagnosis Rheumatologist 
Diagnosis 
Modified Definition 
  N % 
positive 
N % 
positive 
N % 
positive 
Overall N 166  94  47  
Meet ACR SLE 
criteria 
  6.6%  10.6%  14.9% 
Meet SLICC SLE 
criteria 
  14.5%  23.4%  34.0% 
              
 
